For topical use only. Not for oral, ophthalmic or intravaginal use.
- Trade Name: Aklief (Galderma)
- Indications: Indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
- Class: Retinoic acid receptors (RAR) agonist, Retinoid
- Half-life: 2–9 hours
- FDA Approval Date: 10/04/2019
- Clinically important, potentially hazardous interactions with:
None known - Pregnancy: Available data from clinical trials in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
